NCT03765229 2024-01-10An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV MelanomaUNC Lineberger Comprehensive Cancer CenterPhase 2 Completed11 enrolled 12 charts